Noemí Barja

ORCID: 0000-0003-0806-7827
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Imaging and Diagnostics
  • Diabetes Treatment and Management
  • Cardiac Valve Diseases and Treatments
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Cardiovascular Function and Risk Factors
  • Cardiovascular Issues in Pregnancy
  • Acute Myocardial Infarction Research
  • Cardiac electrophysiology and arrhythmias
  • Potassium and Related Disorders
  • Ion channel regulation and function
  • Cardiac Structural Anomalies and Repair
  • Diabetes Management and Education
  • Cardiomyopathy and Myosin Studies
  • Congenital Heart Disease Studies
  • Cardiac pacing and defibrillation studies
  • Diabetes Management and Research
  • Shoulder Injury and Treatment
  • Mechanical Circulatory Support Devices
  • Shoulder and Clavicle Injuries
  • Pharmaceutical Practices and Patient Outcomes

Central University Hospital of Asturias
2020-2023

Spanish National Centre for Cardiovascular Research
2021

Instituto de Investigación Sanitaria del Principado de Asturias
2020

Background: Coronary artery disease (CAD) is the most frequent cause of ST-segment elevation myocardial infarction (STEMI). Etiopathogenic and prognostic characteristics in young patients may differ from older women present worse outcomes than men. We aimed to evaluate clinical prognosis men with premature STEMI. Methods: A total 1404 consecutive were referred our institution for emergency cardiac catheterization due STEMI suspicion (1 January 2014–31 December 2018). Patients confirmed...

10.3390/jcm10061314 article EN Journal of Clinical Medicine 2021-03-23

Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitors) are new glucose-lowering drugs (GLDs) with demonstrated cardiovascular benefits in patients heart disease and type-2 diabetes mellitus (T2DM). However, their safety efficacy when prescribed at hospital discharge unexplored. This prospective, observational, longitudinal cohort study included 104 consecutive T2DM discharged from the cardiology department between April 2018 February 2019. Patients were classified based on SGLT-2...

10.3390/jcm9082600 article EN Journal of Clinical Medicine 2020-08-11

The use of mitral transcatheter edge-to-edge repair (TEER) is rapidly increasing. Anatomical changes have been described after TEER with the MitraClip system in patients functional regurgitation (MR), although no study has yet evaluated such anatomical impacts treated G4 generation. This research constituted a prospective, single-center, observational including consecutive MR. Mitral three-dimensional images were obtained transesophageally echocardiography before and immediately TEER....

10.3390/jcm12041486 article EN Journal of Clinical Medicine 2023-02-13

Background: Long QT syndrome (LQTS) is an inheritable arrhythmogenic disorder associated with life-threatening arrhythmic events (LAEs). In general, patients LQTS2 (KCNH2) and LQTS3 (SCN5A) are considered to be a greater risk of LAEs than LQTS1 (KCNQ1) patients. Gender differences also important. Series analyzing families the same pathogenic variants may help in progress elaborating strong specific genotype-phenotype management strategies. this manuscript, we describe phenotype seven...

10.3390/jcm9123846 article EN Journal of Clinical Medicine 2020-11-26

Abstract Introduction Diabetes Mellitus (DM) is an importan Cardiovascular Risk-factor and glucose-lowering drugs have shown to improve cardiovascular prognosis. We believe that specific training programs in DM are necessary, so we developed a web platform (Tradicar.es) guide provide educational tools. Objectives To evaluate characteristics of patients the impact on active glycemic control strategies after continuous system. Methods created allows direct consult with experts diabetes...

10.1093/ehjci/ehaa946.3484 article EN European Heart Journal 2020-11-01

Abstract Background In recent years, the paradigm of glycemic treatment has changed due to cardiovascular impact newer glucose-lowering drugs (GLD) (sodium-glucosa cotransporter 2 inhibitor (SGLT2i) and GLP-1 receptor agonist (GLP1a)). The cardiological patient with type diabetes (2DM) is a very high risk in which benefit these therapies greater. However, date, different studies have demonstrated efficacy safety GLD only outpatient setting. So its when they are initiated discharge after...

10.1093/ehjci/ehaa946.3349 article EN European Heart Journal 2020-11-01

10.24875/recice.m21000247 article EN cc-by-nc-nd REC interventional cardiology (English Edition) 2021-11-15
Coming Soon ...